AIHA Catalyst    JOEH    Find Consultants    Job Board    Member Center    Marketplace
About AIHA      Membership      Get Involved      AIHA University      Events      IH/OEHS Careers      Public Resources
We believe that worker health and safety is a fundamental human right, and that’s why we tirelessly work to promote and advance the occupational and environmental health and safety profession and those who practice it.
A Risk Assessment Approach to Surface Contamination Under USP 800 (AIHce EXP 2022 OnDemand)
Course Description:
Recorded at AIHce EXP 2022

The U.S. Pharmacopeial Corporation (USP) sets standards for the safe handling of hazardous drugs. The recommendation for periodic surface sampling for hazardous drugs in pharmacies, hospitals and clinics, has driven significant sampling activity in the healthcare industry. Because no safe threshold limits have been specified or are openly available, interpretation of the swab sampling results has proven to be a challenge. Hazardous drug residues on surfaces represent a hazard. A residue does not correlate directly to exposure. The risk for exposure is influenced by variables such as the location, environment, exposure and administrative controls and tasks performed. The AIHA Health Care Working Group has developed a draft guidance document to assist in the implementation of drug sampling programs. This session will present: 1) approaches for developing acceptable surface limits; 2) practical recommendations for sampling; 3) interpretations of swab results; and 4) challenges of bringing IH concepts to pharmacies and hospital personnel.

Learning Outcomes
At the end of this lecture, attendees will:
  • • Outline the USP requirements and recommendations regarding hazardous drug surface sampling.
  • • Recognize there are no published or accepted health-based surface limits available for hazardous drugs.
  • • Discuss the difference between drug hazard and exposure risk.
  • • Explain the pending AIHA Health Care Working Group Guidance for USP Hazardous Drug Swab Sampling.
  • • Prepare and implement a strategy for USP surface sampling for hazardous drugs.
  • • Develop USP sampling plans to gain value and actionable insights.
  • • Leverage USP swab sampling result to reduce exposure risk.
  • • Integrate this topic with feedback and discussion amongst IH professionals at the national level.

Contact Hours:
1

Presentation Date:
05/24/2022

Presenters:
Amy Snow
Janet Gould, PhD DABT CIH
Elaine Strauss, PharmD, MS, BCSCP
Matthew Meiners, CIH

Session recordings are available for 90 days from purchase.


Stock #: AOD22_I4
ISBN #: 
Author/Editor: 

Member $25/Non-Member $35/Student $25

Your Price: $35.00

Add to Cart

AIHA®
3120 Fairview Park Drive, Suite 360 | Falls Church, VA 22042 | Phone +1 703-849-8888


© American Industrial Hygiene Association

AIHA's Twitter AIHA's Facebook AIHA's LinkedIn AIHA's You Tube